Status:
TERMINATED
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
Lead Sponsor:
Pfizer
Conditions:
Angina, Unstable
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty ...
Detailed Description
The study was prematurely discontinued on November 30, 2008 due to delay in meeting pre-defined protocol recruitment milestones. There were no safety concerns regarding the study in the decision to te...
Eligibility Criteria
Inclusion
- Patients more than 18 years
- Ischemic pain of more than 10 minutes within 24 hours before enrollment
- At least two of the following three risk factors : Age more than 60 years ( or more than 50 in case of diabetics), Raised cardiac enzyme levels, abnormal ECG findings
Exclusion
- Contraindications to use of anticoagulants
- Active bleeding or abnormal coagulation tests
- Ischemic stroke within last 6 months or hemorrhagic stroke
- Lumbar or spinal puncture within last 48 hours
- S creatinine levels more than 2
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
173 Patients enrolled
Trial Details
Trial ID
NCT00435487
Start Date
June 1 2007
End Date
December 1 2008
Last Update
October 17 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India, 500 001
2
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India, 500 034
3
Pfizer Investigational Site
Nagpur, Maharashtra, India, 440 012
4
Pfizer Investigational Site
Pune, Maharashtra, India, 411 001